Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia


You May Also Like

Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY

Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America SEATTLE, March ...

Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd.

DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology ...